Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5

Headache

Volumn 50, Issue 3, 2010, Pages 431-441

  Schankin, Christoph J ^a   Kruse, Lars S ^c   Reinisch, Veronika M ^a   Jungmann, Steffen ^a   Kristensen, Julie C ^c   Grau, Stefan ^a   Ferrari, Uta ^a   Sinicina, Inga ^b   Goldbrunner, Roland ^a   Straube, Andreas ^a   Kruuse, Christina ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CGMP; Endothelial cells; Migraine; Nitric oxide; Phosphodiesterases; Stroke

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; CYCLIC AMP; CYCLIC GMP; MESSENGER RNA; NITRIC OXIDE; PHOSPHODIESTERASE 2A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN BLOOD VESSEL; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; HEADACHE; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; CEREBRAL ARTERIES; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEADACHE; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 77749279859     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01512.x     Document Type: Article

References (44)

1. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995 9 : 1319 1330.
2. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci. 2008 27 : 2783 2802.
3. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008 120 : 157 171.
4. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev. 2006 58 : 488 520.
5. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab. 2002 22 : 1124 1131.
6. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 126 : 241 247.
7. Schalcher C, Schad K, Brunner-La Rocca HP, et al. Interaction of sildenafil with cAMP-mediated vasodilation in vivo. Hypertension. 2002 40 : 763 767.
8. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990 37 : 671 681.
9. Liu Y, Shakur Y, Yoshitake M, Kambayashi JJ. Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001 19 : 369 386.
10. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006 26 : 1304 1309.
11. Kruse LS, Sandholdt NT, Gammeltoft S, Olesen J, Kruuse C. Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. Neurosci Lett. 2006 404 : 202 207.
12. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 2006 176 : 213 254.
13. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997 349 : 401 402. (Pubitemid 27077677)
14. Kruuse C, Khurana TS, Rybalkin SD, et al. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. Eur J Pharmacol. 2005 521 : 105 114.
15. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab. 2004 24 : 1352 1358.
16. Edvinsson L, Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia. 2008 28 : 1245 1258.
17. Ferrari U, Empl M, Kim KS, Sostak P, Forderreuther S, Straube A. Calcineurin inhibitor-induced headache: Clinical characteristics and possible mechanisms. Headache. 2005 45 : 211 214.
18. Stins MF, Badger J, Sik KK. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog. 2001 30 : 19 28.
19. Keefer LK, Nims RW, Davies KM, Wink DA. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol. 1996 268 : 281 293.
20. Thomas DD, Espey MG, Ridnour LA, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA. 2004 101 : 8894 8899.
21. Hanafy KA, Krumenacker JS, Murad F. NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit. 2001 7 : 801 819.
22. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004 110 : 675 680.
23. Iversen HK. Human migraine models. Cephalalgia. 2001 21 : 781 785.
24. Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol. 2004 190 : 446 455.
25. Black KL, Yin D, Ong JM, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 2008 1230 : 290 302.
26. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007 32 : 568 572.
27. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Report of seven cases. Neurosurgery. 2001 48 : 723 728.
28. Sobey CG, Quan L. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. Am J Physiol. 1999 277 : H1718 H1724.
29. Willette RN, Shiloh AO, Sauermelch CF, et al. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors. J Cereb Blood Flow Metab. 1997 17 : 210 219.
30. Zhang L, Zhang RL, Wang Y, et al. Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke. 2005 36 : 847 852.
31. Klausen P, Bjerregaard MD, Borregaard N, Cowland JB. End-stage differentiation of neutrophil granulocytes in vivo is accompanied by up-regulation of p27kip1 and down-regulation of CDK2, CDK4, and CDK6. J Leukoc Biol. 2004 75 : 569 578.
32. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol. 2003 64 : 533 546.
33. Maurice DH. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci. 2005 10 : 1221 1228.
34. Zhu B, Strada S, Stevens T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2005 289 : L196 L206.
35. Thompson WJ, Ashikaga T, Kelly JJ, et al. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol. 2002 63 : 797 807.
36. Malinski T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1993 13 : 355 358. (Pubitemid 23129387)
37. Thomsen LL. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia. 1997 17 : 873 895.
38. Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: Implications for migraine pathophysiology. Brain. 2001 124 : 2490 2502.
39. Kim D, Rybalkin SD, Pi X, et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001 104 : 2338 2343.
40. Busch CJ, Liu H, Graveline AR, Bloch KD. Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006 290 : L747 L753.
41. Martinez SE, Beavo JA, Hol WG. GAF domains: Two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv. 2002 2 : 317 323.
42. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007 76 : 481 511.
43. De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci. 2008 267 : 3 16.
44. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002 22 : 54 61.